Form 13-F position report

PROKIDNEY CORP ORD SHS CL A(CY

Reported by MORGAN STANLEY

PROK CUSIP G7S53R104 Manager CIK 0000895421

Reported 10,337,223 shares, down 3,636,134 (26.0%) from the prior quarter.

Reported value -61.6%; share count -26.0% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q1 2025
Shares 10,337,223 Quarter-end amount reported
Reported value $9,057,477 Fair value at quarter end
Consecutive quarters held 11 Through Q1 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-09-30 93267000
2022-12-31 75099816
2023-03-31 108797493
2023-06-30 108491565
2023-09-30 47111560
2023-12-31 19931016
2024-03-31 16935753
2024-06-30 35542922
2024-09-30 27399142
2024-12-31 23614975
2025-03-31 9057477
2025-06-30 3545222
2025-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for PROKIDNEY CORP ORD SHS CL A(CY held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2025 Reduced 0 -5,987,540 (-100.0%) 0 $0 2025-11-14
Q2 2025 Reduced 5,987,540 -4,349,683 (-42.1%) < 0.01% $3,545,222 2025-08-15
Q1 2025 Reduced 10,337,223 -3,636,134 (-26.0%) < 0.01% $9,057,477 2025-05-15
Q4 2024 Reduced 13,973,357 -297,028 (-2.1%) < 0.01% $23,614,975 2025-02-14
Q3 2024 Reduced 14,270,385 -177,956 (-1.2%) < 0.01% $27,399,142 2024-11-14
Q2 2024 Added 14,448,341 +4,121,663 (39.9%) < 0.01% $35,542,922 2024-08-14
Q1 2024 Reduced 10,326,678 -870,521 (-7.8%) < 0.01% $16,935,753 2024-05-15
Q4 2023 Added 11,197,199 +910,833 (8.9%) < 0.01% $19,931,016 2024-02-13
Q3 2023 Added 10,286,366 +590,964 (6.1%) < 0.01% $47,111,560 2023-11-15
Q2 2023 Added 9,695,402 +84,317 (0.9%) 0.01% $108,491,565 2023-08-14
Q1 2023 Reduced 9,611,085 -1,336,410 (-12.2%) 0.01% $108,797,493 2023-05-15
Q4 2022 Added 10,947,495 +595,839 (5.8%) < 0.01% $75,099,816 2023-02-14
Q3 2022 New 10,351,656 +10,351,656 (0.0%) 0.01% $93,267,000 2022-11-14

Who else reported the position

81 managers reported PROKIDNEY CORP ORD SHS CL A(CY for Q1 2025.

Managers reporting PROKIDNEY CORP ORD SHS CL A(CY in Q1 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
SUVRETTA CAPITAL MANAGEMENT LLC Unchanged 12,341,266 0 0.4% $10,813,417 11 qtrs
MORGAN STANLEY This report Reduced 10,337,223 -3,636,134 < 0.01% $9,057,477 11 qtrs
BlackRock Inc Added 6,764,784 +27,650 < 0.01% $5,927,305 3 qtrs
VANGUARD GROUP INC Reduced 5,211,823 -63,882 < 0.01% $4,565,557 11 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 2,322,269 +90,339 < 0.01% $2,035,266 11 qtrs
Bleichroeder LP Unchanged 2,000,000 0 0.47% $1,752,400 11 qtrs
STATE STREET CORPORATION Reduced 1,726,323 -11,541 < 0.01% $1,512,604 10 qtrs
Brown University Unchanged 1,000,000 0 0.41% $880,000 10 qtrs
NORTHERN TRUST CORPORATION Added 907,218 +16,311 < 0.01% $794,905 11 qtrs
Hennion & Walsh Asset Management Inc Added 844,277 +275,630 0.03% $739,756 2 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2025
Filed
May 15, 2025
Filing type
13F-HR
Position type
CLASS A ORD SHS

Voting authority reported

Sole
10,052,849
Shared
0
None
284,374

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.